Unichem Labs bags USFDA nod for Labetalol Hydrochloride Tablets
Mumbai: Drugmaker, Unichem Laboratories Limited, has recently announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Labetalol Hydrochloride Tablets, USP 100 mg, 200 mg, and 300 mg from the United States Food and Drug Administration (USFDA).
The product is a generic version of NORMODYNE (Labetalol Hydrochloride) Tablets 100 mg, 200 mg and 400 mg, of SCHERING CORP SUB SCHERING PLOUGH CORP.
Labetalol Hydrochloride Tablets are indicated for the management of hypertension.
The product will be commercialized from Unichem's Goa Plant.
Read also: Unichem Laboratories gets USFDA approval for its Nebivolol Tablets
Blood pressure is the force exerted by circulating blood against the walls of the body's arteries, the major blood vessels in the body. Hypertension is when blood pressure is too high.
Blood pressure is written as two numbers. The first (systolic) number represents the pressure in blood vessels when the heart contracts or beats. The second (diastolic) number represents the pressure in the vessels when the heart rests between beats.
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Read also: Unichem Labs Chairman says pharma sector recovery may get delayed but not derailed
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.